Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

被引:14
|
作者
Kim, Rathana [1 ,2 ]
Bergugnat, Hugo [2 ]
Larcher, Lise [1 ,2 ]
Duchmann, Matthieu [1 ]
Passet, Marie [1 ,2 ]
Gachet, Stephanie [1 ]
Cuccuini, Wendy [2 ,3 ]
Lafage-Pochitaloff, Marina [3 ,4 ]
Pastoret, Cedric [5 ]
Grardel, Nathalie [6 ]
Asnafi, Vahid [7 ]
Schaefer, Beat W. [8 ]
Delabesse, Eric [9 ]
Itzykson, Raphael [1 ,10 ]
Ades, Lionel [1 ,10 ]
Hicheri, Yosr [11 ]
Chalandon, Yves [12 ]
Graux, Carlos [13 ,14 ]
Chevallier, Patrice [15 ]
Hunault, Mathilde [16 ]
Leguay, Thibaut [17 ]
Huguet, Francoise [9 ]
Lheritier, Veronique [18 ]
Dombret, Herve [10 ]
Soulier, Jean [1 ,2 ]
Rousselot, Philippe [19 ]
Boissel, Nicolas [10 ]
Clappier, Emmanuelle [1 ]
机构
[1] Univ Paris Cite, Inst Rech St Louis IRSL, Inst Natl Sante & Recherche Med INSERM U944, Ctr Natl Rech Sci CNRS UMR 7212 GenCellDis, Paris, France
[2] Hop St Louis, Assistance Publ Hop Paris AP HP, Lab Hematol, Paris, France
[3] Grp Francophone Cytogenet Hematol GFCH, Paris, France
[4] Aix Marseille Univ, Hop Timone Enfant, AP HM, Lab Cyto Genet Hematol, Marseille, France
[5] Ctr Hosp Univ Rennes, Lab Hematol, Rennes, France
[6] Ctr Hosp Reg Univ Lille, Lab Hematol, Lille, France
[7] Hop Necker Enfants Malad, AP HP, Lab Oncohematol, Paris, France
[8] Univ Hosp Zurich, Dept Hematol, Zurich, Switzerland
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Univ Paris Cite, Hop St Louis, AP HP, Dept Hematol Clin,Inst Rech St Louis, Paris, France
[11] Aix Marseille Univ, Inst Paoli Calmettes, Hematol Dept, CNRS,INSERM,CRCM, Marseille, France
[12] Hop Univ Geneve, Hematol, Geneva, Switzerland
[13] Catholic Univ Louvain, Ctr Hosp Univ UCLouvaine Namur Godinne, Serv Hematol, Yvoir, Belgium
[14] CHU Nantes, Dept Hematol, INSERM UMR 1232, Nantes, France
[15] CHU Nantes, CNRS ERL CRCINA IRS UN 6001, Nantes, France
[16] Univ Nantes, Univ Angers, Dept Malad Sang,SFR ICAT, CHU Angers,FHU GOAL,INSERM,CNRS,CRCI2NA, Angers, France
[17] CHU Bordeaux, Hop Haut Leveque, Dept Hematol, Pessac, France
[18] Hop Lyon Sud, Coordinat Grp GRAALL, HCL, Lyon, France
[19] Univ Paris Saclay, Ctr Hosp Versailles, Hematol Dept, UMR CEA 1184, Le Chesnay, France
来源
BLOOD CANCER DISCOVERY | 2023年 / 4卷 / 02期
关键词
ELDERLY-PATIENTS; TP53; MUTATIONS; CANCER; PROGNOSIS; FREQUENCY; DELETIONS; OUTCOMES; ENTITY;
D O I
10.1158/2643-3230.BCD-22-0154
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss of heterozygosity, mutations, and cytogenetics data in a prospective cohort of Philadelphia (Ph)-negative B-ALL patients ( n = 591, ages 18-84 years), allowing us to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidenc-ing low hypodiploidy in many cases missed by cytogenetics. The proportion of LH-ALL within Ph-negative B-ALL dramatically increased with age, from 3% in the youngest patients (under 40 years old) to 32% in the oldest (over 55 years old). Somatic TP53 biallelic inactivation was the hallmark of adult LH-ALL, present in virtually all cases (98%). Strikingly, we detected TP53 mutations in posttreatment remission samples in 34% of patients. Single-cell proteogenomics of diagnosis and remission bone marrow samples evidenced a preleukemic, multilineage, TP53-mutant clone, reminiscent of age-related clonal hematopoiesis.SIGNIFICANCE: We show that low-hypodiploid ALL is a frequent entity within B-ALL in older adults, relying on somatic TP53 biallelic alteration. Our study unveils a link between aging and low-hypodiploid ALL, with TP53-mutant clonal hematopoiesis representing a preleukemic reservoir that can give rise to aneuploidy and B-ALL.See related commentary by Saiki and Ogawa, p. 102.
引用
收藏
页码:134 / 149
页数:16
相关论文
共 50 条
  • [41] Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Goldberg, Aaron D.
    Winer, Eric S.
    Altman, Jessica K.
    Fathi, Amir T.
    Odenike, Olatoyosi
    Roboz, Gail J.
    Gallacher, Phillip
    Wennborg, Anders
    Hickman, Denice Kaylor
    Attar, Eyal C.
    Sallman, David A.
    BLOOD, 2021, 138
  • [42] Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Daver, Naval G.
    Vyas, Paresh
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S362 - S362
  • [44] Accumulation Of Gene Alterations Of TP53, Crebbp and IKZF1 Is a Prognostic Factor In Adult Acute Lymphoblastic Leukemia
    Tokunaga, Kenji
    Yamaguchi, Shunichro
    Shimomura, Taizo
    Suzushima, Hitoshi
    Okuno, Yutaka
    Mitsuya, Hiroaki
    Asou, Norio
    BLOOD, 2013, 122 (21)
  • [45] Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia
    Bowen Yan
    Qinwei Chen
    Jianfeng Xu
    Wei Li
    Bing Xu
    Yi Qiu
    Leukemia, 2020, 34 : 1816 - 1827
  • [46] Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia
    Yan, Bowen
    Chen, Qinwei
    Xu, Jianfeng
    Li, Wei
    Xu, Bing
    Qiu, Yi
    LEUKEMIA, 2020, 34 (07) : 1816 - 1827
  • [47] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark P.
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S6
  • [48] A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval G.
    Vyas, Paresh
    Xing, Guan
    Renard, Camille
    Bagheri, Taravat
    Curtis, Kelly
    Sallman, David A.
    Wei, Andrew H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S312
  • [49] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [50] Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens
    Kanagal-Shamanna, Rashmi
    Jain, Preetesh
    Luthra, Raja
    Patel, Keyur P.
    Garcia-Manero, Guillermo
    Takahashi, Koichi
    Ravandi, Farhad
    Sasaki, Koji
    Kadia, Tapan M.
    Borthakur, Gautam
    Konopleva, Marina
    Jain, Nitin
    Garris, Rebecca
    Pierce, Sherry
    Estrov, Zeev
    Wierda, William G.
    O'Brien, Susan M.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    BLOOD, 2016, 128 (22)